Page values for "Buprenorphine"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Buprenorphine
brand	`String`
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Opioid analgesics\|Opioid analgesic (partial mu-agonist • kappa antagonist)]] • [[:Category:Schedule III controlled substances\|Schedule III controlled substance]]
mechanism	`String`
uses	`String`	'"`UNIQ--vote-0000004B-QINU`"', '"`UNIQ--vote-0000004C-QINU`"', '"`UNIQ--vote-0000004D-QINU`"', '"`UNIQ--vote-0000004E-QINU`"'
starting_dose	`String`
preparations	`String`
fda_max	`String`	MOUD: typical effective max 24 mg/day sublingual (doses above offer limited additional mu-occupancy due to ceiling). Pain (Belbuca): 900 mcg every 12 hours.
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Sublingual (primary for MOUD) • buccal (Belbuca for pain) • transdermal (Butrans) • SC depot (Sublocade) • IV/IM (Buprenex). Oral swallowed: very low bioavailability due to first-pass; not therapeutic.
onset	`String`	Sublingual analgesic effect 30-60 minutes; MOUD craving suppression within hours; Butrans patch steady-state in 3 days.
duration	`String`	MOUD: 24-72 hours per sublingual dose (long; permits every-other-day or three-times-weekly dosing in stable patients); Butrans patch: 7 days; Sublocade depot: 28+ days; Buprenex IV/IM: 6-8 hours.
halflife	`String`	Buprenorphine sublingual: 24-42 hours (long, contributes to extended dosing intervals). Norbuprenorphine (active metabolite, weaker mu-agonist): 24-48 hours.'"`UNIQ--ref-0000004F-QINU`"'
bioavailability	`String`	~30% (sublingual; the primary therapeutic route); ~10-20% (oral swallowed, low due to first-pass); ~50% (buccal Belbuca); transdermal Butrans bypasses first-pass.'"`UNIQ--ref-00000050-QINU`"'
pregnancy	`String`
legal	`String`